| Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 … EN Oliva, C Alati, V Santini, A Poloni, A Molteni, P Niscola, F Salvi, ... The Lancet Haematology 4 (3), e127-e136, 2017 | 179 | 2017 |
| Differences among young adults, adults and elderly chronic myeloid leukemia patients F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ... Annals of Oncology 26 (1), 185-192, 2015 | 101 | 2015 |
| Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients M Breccia, F Efficace, S Sica, E Abruzzese, M Cedrone, D Turri, M Gobbi, ... Leukemia research 39 (10), 1055-1059, 2015 | 60 | 2015 |
| Multicentre phase III trial on fludarabine, cytarabine (Ara‐C), and idarubicin versus idarubicin, Ara‐C and etoposide for induction treatment of younger, newly … D Russo, M Malagola, A de Vivo, M Fiacchini, G Martinelli, PP Piccaluga, ... British journal of haematology 131 (2), 172-179, 2005 | 49 | 2005 |
| Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study R Latagliata, D Ferrero, A Iurlo, F Cavazzini, F Castagnetti, E Abruzzese, ... Drugs & aging 30, 629-637, 2013 | 46 | 2013 |
| MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: A report from the Italian Lymphoma Study Group. PG Gobbi, C Pieresca, M Federico, N Di Renzo, F Narni, E Iannitto, ... Journal of clinical oncology 11 (4), 712-719, 1993 | 38 | 1993 |
| Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL M Federico, V Clò, M Brugiatelli, M Carotenuto, PG Gobbi, D Vallisa, ... Haematologica 83 (9), 800-811, 1998 | 31 | 1998 |
| Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano … PG Gobbi, C Pieresca, A Frassoldati, M Carotenuto, N Di Renzo, ... Journal of clinical oncology 14 (2), 527-533, 1996 | 29 | 1996 |
| ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL) V Silingardi, M Federico, L Cavanna, P Avanzini, PG Gobbi, M Lombardo, ... Leukemia & Lymphoma 17 (3-4), 313-320, 1995 | 29 | 1995 |
| Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome A Iurlo, A Nobili, R Latagliata, C Bucelli, F Castagnetti, M Breccia, ... Oncotarget 7 (48), 80083, 2016 | 25 | 2016 |
| Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients F Castagnetti, M Breccia, G Gugliotta, B Martino, M D’Adda, F Stagno, ... haematologica 101 (10), 1200, 2016 | 25 | 2016 |
| Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no transplant in cohort of 258 … AM Liberati, ... British Journal of Haematology 85, 292-299, 1993 | 19 | 1993 |
| ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial. M Federico, G Moretti, PG Gobbi, P Avanzini, L Cavanna, M Carotenuto, ... Leukemia 5, 95-101, 1991 | 19 | 1991 |
| Serum selenium concentrations in patients with newly diagnosed lymphoid malignancies P Avanzini, M Vinceti, F Ilariucci, L Masini, M D'Inca, G Vivoli Haematologica 80 (6), 505-511, 1995 | 18 | 1995 |
| Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma: a report from the Italian Lymphoma Study Group (GISL) M Federico, PG Gobbi, G Moretti, P Avanzini, N Di Renzo, L Cavanna, ... American journal of clinical oncology 18 (1), 8-14, 1995 | 16 | 1995 |
| Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres G Longo, M Federico, C Pieresca, P Avanzini, E Iannitto, AU Di Prisco, ... European Journal of Cancer 31 (11), 1763-1767, 1995 | 15 | 1995 |
| Retrospective analysis of mantle cell lymphoma: experience of the Gruppo Italiano per lo Studio dei Linfomi (GISL) V Callea, V Clò, F Morabito, L Baldini, C Stelitano, F Narni, P Avanzini, ... Haematologica 83, 993-997, 1998 | 14 | 1998 |
| A pilot study on the use of the proMACE‐cytaBOM regimen as a first‐line treatment of advanced follicular non‐Hodgkin's lymphoma L Baldini, A Guffanti, P Gobbi, M Colombi, M Federico, P Avanzini, ... Cancer 79 (6), 1234-1240, 1997 | 14 | 1997 |
| Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim results on efficacy, safety and quality of life of an … EN Oliva, V Santini, C Alati, A Poloni, A Molteni, P Niscola, G Sanpaolo, ... Blood, The Journal of the American Society of Hematology 126 (23), 91-91, 2015 | 13 | 2015 |
| EPIDOXORUBICIN VS IDARUBICIN CONTAINING REGIMENS IN INTERMEDIATE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA-PRELIMINARY-RESULTS OF A MULTICENTRIC RANDOMIZED TRIAL M Brugiatelli, M Federico, PG Gobbi, P AvANZINI, V Callea, L Cavanna, ... Haematologica 78, 306-312, 1993 | 13 | 1993 |
